Do I fit the PBS criteria for Ozempic, Wegovy or Mounjaro?

The subsidy rules for GLP-1 medicines are public — but they're scattered and they keep moving. Answer a few questions and this page shows you which criteria group your numbers appear to put you in, so you can have an informed conversation with your own GP. Nothing is prescribed or supplied here, and your answers never leave your browser.

Criteria last reviewed: . PBS listings change — confirm current status on the PBS schedule or with your pharmacist.

The interactive checker needs JavaScript — but the published criteria it walks through fit in one paragraph. There are three groups. Type 2 diabetes is the group the PBS subsidises GLP-1 medicines for: several brands (including Ozempic) are PBS-listed under a Streamlined Authority, typically where blood glucose remains above target despite metformin and/or another oral medicine — co-payment $25.00 (general) or $7.70 (concession); the exception is Mounjaro, which remains a private prescription after its sponsor declined the PBS listing terms. A prior heart attack, stroke or symptomatic peripheral arterial disease with BMI ≥ 35 (≥ 32.5 for people of Asian, Aboriginal or Torres Strait Islander background) is the group covered by the PBS listing the PBAC has recommended for Wegovy (December 2025) — that listing was not yet active at last review, so prescriptions in this group remain private until it takes effect. BMI ≥ 30, or ≥ 27 with at least one weight-related condition (such as high blood pressure, dyslipidaemia or obstructive sleep apnoea) is the TGA-approved indication group for the weight-management brands (Wegovy, Saxenda) — prescriptions on this pathway are private, roughly AUD $400–650 per month. Whether your numbers appear to fall within or outside these groups, none of this is a recommendation to start a medicine — that conversation belongs with your own GP, and the plain-English guide to this medicine family is a good place to prepare for it. Confirm current listing status on the PBS schedule.

1. Have you been diagnosed with type 2 diabetes?

Type 2 diabetes is the pathway most GLP-1 brands are PBS-subsidised under. If you have type 1 diabetes, these criteria don't apply — that's a specialist conversation.

This page provides general information about publicly published Australian subsidy (PBS) and indication (TGA) criteria. It is educational only — it is not medical advice, it does not diagnose, no medicine is prescribed, recommended, or supplied through this site, and it doesn't replace the judgement of a prescriber who knows you. Your answers are processed entirely in your browser and are not stored or sent anywhere. If something is urgent, call 000.

Do I fit the PBS criteria for Ozempic, Wegovy or Mounjaro?

Where your answers appear to put you